Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338415 · ClinicalTrials.gov registry record · Phase 3
FUTURE 3 Study Extension
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT01338415 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 58 participants.
The verdict
NCT01338415, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).
Interventions
- DRUG Bosentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2011-03-08 |
| Est. Completion | 2020-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01338415
The ClinicalTrials.gov registry entry for NCT01338415 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bosentan is the first listed.
NCT01338415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01338415 about?
NCT01338415 is a clinical study titled "FUTURE 3 Study Extension". The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).
What is the current status of trial NCT01338415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2011-03-08. Estimated completion is 2020-05-29.
What interventions are being tested in trial NCT01338415?
The interventions under investigation include: Bosentan (DRUG).
Who is sponsoring clinical trial NCT01338415?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.